Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks
Executive Summary
‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.
You may also be interested in...
Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs
A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO offers possible scenarios of how developers may react.
Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs
A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO and offers possible scenarios of how developers may react.
Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.